News
Project ATLAS: Better Supportive Therapy for Multiple Myeloma Patients
A research team led by assoc. prof. Dominik Dytfeld from PUMS Department of Hematology and Bone Marrow Transplantation has identified a more efficient supportive therapy method for patients after auto-HSCT who suffer from multiple myeloma.
Results of the international phase III ATLAS clinical trial show that the use of carfilzomib, lenalidomide, and dexamethasone (KRd) as maintenance therapy after induction and autologous stem cell transplantation (ASCT) significantly reduced the risk of disease progression by 44%, compared with standard lenalidomide maintenance therapy.
The Atlas research has been designed and conducted by the Polish Myeloma Consortium in cooperation with prof. Andrzej Jakubowiak - Director of the Myeloma Program at the University of Chicago and an alumnus of PUMS. 159 patients from Poland and 21 from the USA took part in the innovative trial.
More details about the findings and the project can be found at https://ascopost.com/issues/august-10-2022/atlas-trial-risk-adapted-triplet-maintenance-therapy-may-benefit-some-patients-with-multiple-myeloma/.